Form 3 - Initial statement of beneficial ownership of securities

S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Form 3 - Initial statement of beneficial ownership of securities

Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Ocugen Charts.

Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Ocugen Charts.

Ocugen Inc News

Form S-8 - Securities to be offered to employees in employee benefit plans
Thursday 6 March 2025 (6 days ago) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Thursday 6 March 2025 (6 days ago) • Edgar (US Regulatory)

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
Wednesday 5 March 2025 (6 days ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 5 March 2025 (6 days ago) • Edgar (US Regulatory)

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
Tuesday 4 March 2025 (1 week ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 4 March 2025 (1 week ago) • Edgar (US Regulatory)

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
Friday 28 February 2025 (2 weeks ago) • GlobeNewswire Inc.

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Saturday 22 February 2025 (3 weeks ago) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Friday 14 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 13 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Wednesday 12 February 2025 (4 weeks ago) • GlobeNewswire Inc.

Form 8-K/A - Current report: [Amend]
Saturday 8 February 2025 (1 month ago) • Edgar (US Regulatory)

More Ocugen Inc News Articles

Commonwealth Bank Of Aus...

Sterling vs AUD

National Australia Bank

JP Morgan Chase

AUD vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions